Brown Advisory Securities LLC boosted its stake in shares of Pfizer Inc. (NYSE:PFE) by 7.7% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 70,529 shares of the biopharmaceutical company’s stock after acquiring an additional 5,040 shares during the period. Brown Advisory Securities LLC’s holdings in Pfizer were worth $2,517,000 at the end of the most recent quarter.
A number of other large investors also recently bought and sold shares of PFE. Vanguard Group Inc. raised its position in shares of Pfizer by 2.3% in the second quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock valued at $14,062,088,000 after buying an additional 9,239,499 shares during the last quarter. Franklin Resources Inc. raised its position in shares of Pfizer by 0.9% in the second quarter. Franklin Resources Inc. now owns 46,167,213 shares of the biopharmaceutical company’s stock valued at $1,550,754,000 after buying an additional 389,629 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Pfizer by 4.8% in the second quarter. Dimensional Fund Advisors LP now owns 44,286,544 shares of the biopharmaceutical company’s stock valued at $1,487,617,000 after buying an additional 2,028,313 shares during the last quarter. Fisher Asset Management LLC raised its position in shares of Pfizer by 3.2% in the third quarter. Fisher Asset Management LLC now owns 35,120,799 shares of the biopharmaceutical company’s stock valued at $1,253,813,000 after buying an additional 1,085,437 shares during the last quarter. Finally, LSV Asset Management raised its position in shares of Pfizer by 0.6% in the second quarter. LSV Asset Management now owns 33,275,572 shares of the biopharmaceutical company’s stock valued at $1,117,726,000 after buying an additional 199,100 shares during the last quarter. Institutional investors own 69.75% of the company’s stock.
Shares of Pfizer Inc. (PFE) opened at $36.94 on Friday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15. Pfizer Inc. has a 1-year low of $30.90 and a 1-year high of $37.37. The stock has a market cap of $220,190.00, a PE ratio of 22.66, a P/E/G ratio of 2.30 and a beta of 1.01.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The firm had revenue of $13.17 billion during the quarter, compared to analyst estimates of $13.17 billion. During the same quarter in the prior year, the firm posted $0.61 earnings per share. Pfizer’s quarterly revenue was up .9% on a year-over-year basis. research analysts expect that Pfizer Inc. will post 2.59 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Investors of record on Friday, February 2nd will be issued a $0.34 dividend. The ex-dividend date is Thursday, February 1st. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.68%. This is a positive change from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s dividend payout ratio is currently 78.53%.
Pfizer declared that its Board of Directors has authorized a stock buyback program on Monday, December 18th that authorizes the company to buyback $10.00 billion in shares. This buyback authorization authorizes the biopharmaceutical company to reacquire shares of its stock through open market purchases. Shares buyback programs are usually an indication that the company’s board of directors believes its stock is undervalued.
A number of equities research analysts have recently commented on the stock. Zacks Investment Research upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $41.00 target price for the company in a research report on Wednesday. Morgan Stanley set a $41.00 target price on shares of Pfizer and gave the company a “buy” rating in a research report on Friday, January 5th. BMO Capital Markets set a $39.00 target price on shares of Pfizer and gave the company a “buy” rating in a research report on Monday, January 8th. Vetr cut shares of Pfizer from a “buy” rating to a “hold” rating and set a $37.98 target price for the company. in a research report on Monday, January 15th. Finally, Jefferies Group set a $40.00 target price on shares of Pfizer and gave the company a “neutral” rating in a research report on Tuesday, January 16th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and thirteen have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $38.94.
In other Pfizer news, EVP Rady A. Johnson sold 8,000 shares of the stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $37.07, for a total transaction of $296,560.00. Following the completion of the transaction, the executive vice president now owns 46,963 shares of the company’s stock, valued at $1,740,918.41. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Alexander R. Mackenzie sold 6,750 shares of the stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $37.00, for a total transaction of $249,750.00. Following the transaction, the insider now directly owns 103,458 shares of the company’s stock, valued at approximately $3,827,946. The disclosure for this sale can be found here. Insiders sold 29,450 shares of company stock valued at $1,065,220 in the last three months. 0.06% of the stock is currently owned by insiders.
ILLEGAL ACTIVITY NOTICE: “Pfizer Inc. (PFE) Shares Bought by Brown Advisory Securities LLC” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/01/21/pfizer-inc-pfe-shares-bought-by-brown-advisory-securities-llc.html.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.